[go: up one dir, main page]

AU6655898A - Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands - Google Patents

Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands

Info

Publication number
AU6655898A
AU6655898A AU66558/98A AU6655898A AU6655898A AU 6655898 A AU6655898 A AU 6655898A AU 66558/98 A AU66558/98 A AU 66558/98A AU 6655898 A AU6655898 A AU 6655898A AU 6655898 A AU6655898 A AU 6655898A
Authority
AU
Australia
Prior art keywords
hypothalamic
pituitary
adrenal
modulation
receptor ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU66558/98A
Other languages
English (en)
Inventor
Jose F. Caro
Libbey S. Craft
Mark L. Heiman
Lawrence J. Slieker
Thomas W. Stephens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU6655898A publication Critical patent/AU6655898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU66558/98A 1997-02-25 1998-02-24 Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands Abandoned AU6655898A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80466997A 1997-02-25 1997-02-25
US08804669 1997-02-25
PCT/US1998/002906 WO1998036767A1 (fr) 1997-02-25 1998-02-24 Modulation de l'axe hypotalamo-hypophyso-adrenalo-adipeux au moyen de ligands du recepteur de la leptine

Publications (1)

Publication Number Publication Date
AU6655898A true AU6655898A (en) 1998-09-09

Family

ID=25189531

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66558/98A Abandoned AU6655898A (en) 1997-02-25 1998-02-24 Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands

Country Status (5)

Country Link
EP (1) EP0991420A1 (fr)
JP (1) JP2001514620A (fr)
AU (1) AU6655898A (fr)
CA (1) CA2282341A1 (fr)
WO (1) WO1998036767A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866547A (en) * 1998-01-20 1999-02-02 Beth Israel Deaconess Medical Center Methods of neuroendocrine regulation of affective disorders
WO2007080404A2 (fr) * 2006-01-12 2007-07-19 Asterion Limited Ligands de leptines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0725079A1 (fr) * 1995-01-31 1996-08-07 Eli Lilly And Company Protéine contre obesité

Also Published As

Publication number Publication date
WO1998036767A1 (fr) 1998-08-27
JP2001514620A (ja) 2001-09-11
EP0991420A1 (fr) 2000-04-12
CA2282341A1 (fr) 1998-08-27

Similar Documents

Publication Publication Date Title
AU1718397A (en) Micromixer
AU5469498A (en) Hinge connection
AUPO788597A0 (en) Closure
AU2784397A (en) Contrast agents
AU4578297A (en) New combination
AUPO832997A0 (en) Polymeric closure
AU6827898A (en) Detergent-package combination
AU1626297A (en) Syringe assembly
AU7539198A (en) Closure
AU8072498A (en) Heregulin-like factor
AU9549098A (en) Facilitation of the choice of paint
AU2624797A (en) Balanced modulator
AU5490298A (en) Syringe
AU6655898A (en) Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands
AU6090898A (en) Substituted 4-benzoyl-pyrazoles
AUPO499097A0 (en) Closure
AU2093997A (en) Spreader
AU6904398A (en) Radiotelephone unit
AU6947298A (en) Modulating the rad-nm23 interaction
AU6560598A (en) Functionally-graded materials
AUPO857097A0 (en) The mixer
HK1022679B (en) Container-piling spreader
AU7456998A (en) Spreader
AUPO931197A0 (en) The anchor
AUPO636797A0 (en) The neckbag